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Abstract: The definition New psychoactive substances (NPS) refers to emerging drugs whose 
chemical structures are similar to other psychoactive compounds but not identical, representing a 
“legal” alternative to internationally controlled drugs. There are many categories of NPS, such as 
synthetic cannabinoids, synthetic cathinones, phenylethylamines, piperazines, ketamine derivatives 
and tryptamines. Tryptamines are naturally occurring compounds, which can derive from the amino 
acid tryptophan by several biosynthetic pathways: their structure is a combination of a benzene ring 
and a pyrrole ring, with the addition of a 2-carbon side chain. Tryptamines include serotonin and melatonin as well as 
other compounds known for their hallucinogenic properties, such as psilocybin in ‘Magic mushrooms’ and 
dimethyltryptamine (DMT) in Ayahuasca brews.  
Aim: To review the scientific literature regarding tryptamines and their derivatives, providing a summary of all the 
available information about the structure of these compounds, their effects in relationship with the routes of 
administration, their pharmacology and toxicity, including articles reporting cases of death related to intake of these 
substances.  
Methods: A comprehensive review of the published scientific literature was performed, using also non peer-reviewed 
information sources, such as books, government publications and drug user web fora.  
Conclusions: Information from Internet and from published scientific literature, organized in the way we proposed in this 
review, provides an effective tool for specialists facing the emerging NPS threat to public health and public security, 
including the personnel working in Emergency Department.  
Keywords: Clinical effects, Emergency Departments, Fatalities, Forensic Toxicology, Intoxication, New Psychoactive 
Substances (NPS), Tryptamines. 
INTRODUCTION 
 The New psychoactive substances (NPS) are defined by 
European Community (2005) as “substances of abuse either 
in a pure form or preparation that are not controlled by the 
1961 Single Convention on Narcotics Drugs or the 1971 
Convention on Psychotropic Substances, but which may 
pose a public health threat comparable to scheduled 
substances” [1]. According to Zuba, “they are created 
usually by manipulating already existing psychoactive 
substances or, less, by finding drugs with a new chemical 
structure that may produce similar effects to those of the 
illegal drugs of abuse”  [2]. They may be formulated as 
“bulk powders, liquids, tablets, capsules, blotters,” or herbal 
preparations, indeed on the web sites these drugs are sold as 
“research chemicals,” “incense,” “bath salts,” or “plant-
growth fertilizers,” equipped with labels specifying that the 
products are “not for human consumption” or “not for sale to 
minors” [3]. The International Narcotics Control Board 
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regards the Internet “as a growing source of on-line drug 
trafficking”: products purchased on Internet may vary over 
time proposing chemicals always different, not listed in 
literature, meaning that users are often unaware of what or 
how much they are taking [4], causing increasing risks to 
public health. The phenomenon of marketing illicit drug 
‘‘derivatives’’ grew mainly because of their easy availability 
on the Internet or in “head shops”. The use of NPS has 
increased dramatically in recent years: only in the European 
Union, the number of NPS identified has risen “from 14 at 
the end of 2005 to 236 by the end of 2012” [5]. The majority of 
new recreational synthetic drugs fall into one of the following 
psychoactive drug categories: synthetic cannabinoids, synthetic 
cathinones, phenylethylamines, piperazines, ketamine 
derivatives and tryptamines. 
 Tryptamines are a group of monoamine alkaloids (Fig. 1), 
which can be synthesized by decarboxylation of the 
aminoacid tryptophan: they can be found in plants, fungi, 
animals, microbes and amphibia [6].  
 Tryptamines have an indole ring structure, a fused double 
ring comprising of a pyrrole ring and a benzene ring, joined 
to an amino group by 2 carbon side chain.  
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 The tryptamines play a fundamental role in human life: 
serotonin (5-hydroxytryptamine, 5-HT), one of the most 
important signaling hormones [7] in the body, is a 
tryptamine natural derivative involved in regulation and 
modulation of multiple processes within the central nervous 
system, such as sleep, cognition, memory, temperature 
regulation and behavior [8]. Moreover, mammalian brain 
contains very low concentrations (in the low ng/g range) of 
tryptamine, which may act as a neurotransmitter or modulator 
[9]: it acts as a serotonin releasing agent and it is an enhancer 
of serotonergic activity [10]. Gibbons in his publication, 
defines the nature “an astounding chemist (..) able to produce 
compounds that have profound effects on the central nervous 
system (CNS)”[11]. Naturally occurring derivatives of the 
tryptamines are present in the ‘Magic mushrooms’ belonging 
to Psilocybe cubensis species, which contain psilocybin  
(4-phosphoryloxy-N,N-dimethyltryptamine) and psilocin  
(4-hydroxy-N,N-dimethyltryptamine), the latter showing 
marked similarities with serotonin (Fig. 2).  
 Another example of the ability of the natural world to 
create hallucinogenic substances, is the 5-hydroxy-N,N-
dimethyltryptamine (bufotenine), a positional isomer of 
psilocin [12], which is contained in the skin and glands of 
various species of toad of the genus Bufo [13]. Chemical 
modifications of the nucleus structure of the tryptamine 
molecule produce new compounds which may cause 
alterations of the physical and mental status: substitutions on 
the indole ring, on the two carbons of the side chain and 
alkylation of the side-chain nitrogen result in new 
neuroactive compounds, ranging from toxic substances to 
anti-migraine drugs, such as Sumatriptan [14], Rizatriptan 
and Zolmitriptan (Fig. 3). 
 Tryptamines show agonist action at multiple receptors, 
including 5HT2a-1a-2c [15] serotonin receptors [16], and 
several ion channels [17]. In general, tryptamines seem to 
have hallucinogenic properties, rather than stimulant or 
entactogenic characteristics: their alpha methylation leads to 
stimulant activity [α-methyltryptamine (AMT), 5-methoxy-
α-methyltryptamine (5-MeO-AMT)], being the presence of 
an alpha carbon methyl group, a characteristic in common 
with amphetamine [14, 18]. The synthesis and the effects of 
these compounds have been fully investigated by Alexander 
T. Shulgin who described his experiences within the book 
Tihkal [19]: he identified 55 molecules and he tested these 
substances on volunteers to assess their effects according to 
his rating scale. Recreational use of tryptamines requires 
only minute amounts to produce psychotropic phenomena 
and has been associated to intoxications and fatalities for 
several reasons, including low toxic concentrations. Moreover, 
these molecules are not routinary detected with common 
screening panels, so far in emergency rooms the test could 
result completely negative leading to misunderstanding 
diagnosis or therapy and limited evaluation of the phenomenon. 
It is very important to organize the information pertaining to 
these substances to provide a tool for specialists facing this 
emerging threat to public health and public security. For this 
reason a comprehensive review of the scientific literature 
and internet sites regarding tryptamines and their derivatives 
was carried out, providing a summary of all the available 
information about the structure of these compounds, their 
effects in relationship with the routes of administration  
and their toxicity, including articles reporting cases of  
death related to intake of these substances and analytical 
methods for the determination and quantification of some 
tryptamines.  
CLASSIFICATION OF TRYPTAMINES BASED ON 
THEIR CHEMICAL STRUCTURES 
 Several classifications have been suggested for these 
substances. Nichols classified tryptamines in two main 
groups: -the simple tryptamines, including dimethyltryptamine 
(DMT), and the ergolines (a group of chemical compounds 
that were originally synthesized from a fungus ergot, among 
which is the lysergic acid diethylamide (LSD). Fantegrossi 
divided tryptamines in three subgroups: (1) simple tryptamines, 
without modification of the indole ring; (2) tryptamines 
having a modification on the 4-position on the indole ring; 
(3) tryptamines having a modification on the 5-position. Only 
 
Fig. (1). Tryptamine structure. 
 
Fig. (3). Tryptamine structure as template for new psychoactive 
compounds. 
 
Fig. (2). Psilocin and serotonin structure. 
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substitutions on the 4-5 positions were considered because 
changes in position 6 or 7 result in reduced hallucinogenic 
activity [14] (Fig. 4). 
STRUCTURE-ACTIVITY RELATIONSHIPS IN 
TRYPTAMINES AND THEIR METABOLISM 
 The effects caused by the administration of tryptamines 
are closely related to their structures, as each of these 
compounds has a different receptor affinity to which are 
related psychoactive phenomena. 
RING UNSUBSTITUTED COMPOUNDS  
 Several compounds belong to this class, including  
α-methyltryptamine (AMT, street name Spirals) and  
α-ethyltryptamine (AET) both showing stimulant activities 
[18]. 
 Alpha-methyltryptamine (AMT) was firstly developed 
as an antidepressant agent called as INDOPAN, in 1960’s by 
the Upjohn Company and used for a short period of time in 
the former Soviet Union [20], but at last it was recognized as 
a toxic substance able to produce psychosis [21]. 
 AMT activity is linked with the release of dopamine and 
its re-uptake inhibition. AMT also acts on serotonin and 
noradrenaline receptors and inhibits MAO activity in vitro 
and in vivo, therefore it is active after oral administration. 
Nagai [16] in his study, developed a method to determine the 
reuptake and release of monoamines (dopamine, serotonin 
and norepinephrine), and “analyzed the effects of various 
designer drugs on monoamine neurotransmission”, using rat 
brain synaptosomes. He disclosed that AMT presented  
the “strongest monoamine re-uptake inhibitory activity  
and release stimulating activity, although monoamine release 
was more dominant than re-uptake inhibition” [16]. 
Furthermore, he discovered that 5-MeO-AMT, “inhibited 
monoamine (dopamine, 5-HT and norepinephrine) re-uptake 
and stimulated monoamine release; its potency was second 
to that of AMT. AMT and 5-MeO-AMT both have a primary 
amine group, which in tryptamine might be indispensable for 
the stimulation of monoamine release” [16]. Illegal use of α-
methyl-tryptamine is based on its hallucinogenic and 
psychedelic visual effects, with doses ranging from 15 to 30 
mg if administered orally. It can be smoked (4-20 mg) as 
freebase, and snorted as well. The onset of action, if orally 
administered, is between 3 and 4 hours, generally lasting up 
to 12-24 hours, but in some subjects the action can last until 
2 days. The onset of action if smoked is in the range of 
seconds or minutes. Uncomfortable feelings are reported, 
such as restlessness and irritability, hyperthermia, anorexia, 
vomiting, inability to sleep, tachycardia, increase in blood 
pressure pupils dilatation, deep tendon reflexes and coordination 
impairment [22]. Wilcox [23] interviewed 15 individuals 
who had used α-methyltryptamine. Most common side effects 
reported were anxiety, nausea and moderately severe 
dysphoria as well as depression (15% severely depressed 
mood on the day after). The 90% of patients reported visual 
hallucinations and 87 % euphoria. Anxiety was lamented in 
35% of cases, in a correlation with crowded environment. 
AMT, as every psychedelic agent can alter judgement and 
 
Fig. (4). Classification of tryptamines. 
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perception and therefore it can cause dangerous behaviours. 
In the US, since 2004, it’s placed as a schedule I substance, 
while in the UK it was completely legal until June 2014 [24]. 
According to the NPSAD (National Program on Substance 
Deaths Abuse) Annual Report, from January to December 
2012 in the UK, α-methyltryptamine has showed the highest 
number of deaths (2 reported in 2011 and 4 reported in 2012) 
compared to tryptamine or 5-methoxy-diallyltryptamine  
(5-MeO-DALT) [25].  
 Also alpha-ethyltryptamine (AET) was firstly introduced 
as an antidepressant agent by Upjohn company in 1960s  
with the name MONASE, but it was withdrawn from the 
market because of an unacceptable incidence of idiosyncratic 
agranulocytosis. AET may induce serotonin neurotoxicity 
[26], similar to that of MDMA and para-chloroamphetamine 
(PCA), as reported in studies on rats. AET inhibits MAO 
activity [27] in vitro and in vivo, as AMT, and it is  
orally active. Lessins [18] studied the effects of these two 
alpha-tryptamine derivatives in mice, observing marked 
stimulation with increased locomotor activity, hyperthermia, 
midriasis and generalized body tremor: AET assumption is 
also correlated with psychedelic, stimulant, and entactogenic 
effects. 
 The dosage reported by Shulgin, for oral administration, 
is 100-150 mg. and it seems to be able to fight opiate 
addiction in anecdotal reports. “It appears to serve well, with 
short term dosage regimens, as an effective tool in kicking 
dependency on opiates” [19].  
 Dimethyl-tryptamine (DMT) was first synthesized in 
1931 by Richard Helmuth Fredrick Manske, but it was 
discovered as a natural product only in 1946, when a 
brazilian chemist and microbiologist, Oswaldo Gonçalves de 
Lima, isolated it from the root bark of Mimosa tenuiflora. 
Since 1955 DMT has been found in at least fifty species of 
plants belonging to ten families [28], in four species of 
animals, and in three species of mammals. The biosynthesis 
of DMT begins with the decarboxylation of tryptophan that 
leads to the production of tryptamine. Further, tryptamine 
undergoes a methylation process, generating the intermediate 
product N-methyltryptamine (NMT). NMT is in turn 
transmethylated to form the final product N,N-dimethyl 
tryptamine. DMT binds several serotonin receptors, acting as 
a partial agonist in particular on the 5-HT2A and 5-HT2C 
receptors. It has also been shown to possess affinity for the 
α1 and α2-adrenergic receptors, dopamine D1, and sigma-1 
(σ1). The psychedelic activity of DMT, similar to LSD and 
mescaline, can probably be attributed to the binding to  
5-HT2A receptor, although the activation of other receptors, 
such as 5-HT2C and sigma-1, may play a very important role 
in the onset of these effects [29]. DMT can be taken orally, 
intravenously or by inhalation. When inhaled, a standard 
dose of DMT is 15–60 mg. The onset of the effects is very 
fast, less than 45 seconds, peak effects are reached within a 
minute and they last usually for about 15 minutes. The 
experiences after injecting a DMT are similar to inhalation in 
duration, intensity and characteristics. If orally administered 
DMT must be associated with a MAOI, as it is deaminated 
by monoamine oxidase and is quickly inactivated. The 
Ayahuasca brew, used in religious rituals of the native 
peoples of the Amazon, is obtained by boiling the Ayahuasca 
vine (Banisteriopsis caapi), that contains monoamine 
oxidase inhibitors (ß-carbolines harmaline, harmine, and 
1,2,3,4 tetrahydroharmine) with the leaves of shrubs of the 
genus Psychotria or Diplopterys, that contains DMT. A 
review on the risk assessment of the use of Ayahuasca has 
been made by Gable, who reported that to achieve the lethal 
dose in humans, it would be necessary to ingest more than 20 
times the ceremonial dose. The brew seems also to have 
minimal dependence potential [30]. 
 Diethyl-tryptamine (DET) has not been found to occur 
naturally and, although presenting structural similarity to 
DMT, it is active when administered orally, due to the 
presence of two ethyl groups linked to its nitrogen atom, 
preventing its degradation by MAO. Its mechanism of action 
is not clear, but, like other psychedelic tryptamines, DET 
could present an agonist activity towards serotonin receptors 
[31, 32]. When orally administered the dosage is 50–100 mg 
and the effects are reported to last about 2–4 hours [33].  
 Dipropyl-tryptamine (DPT) was firstly synthesized in 
the 1950s [34], but it was firstly reported for use in the 
scientific literature only in 1973 [35], as an adjunct in 
psychotherapy of alcoholics. It is found either as its 
crystalline hydrochloride salt or as an oily or crystalline base 
and, as DET, it has not been found to occur naturally. There 
are few peer-reviewed experimental studies that try to 
explain the ways of interaction among DPT and serotonin 
receptors: Nagai revealed a strong inhibition of 5-HT reuptake 
in rat synaptosomes [16], and Thiagaraj also observed a 
moderate affinity partial agonism at the human 5-HT1A 
receptor [34]. Experiences related to DPT assumption are 
mostly psychedelic sensations, such as an increase of music 
and colors intensity, the vision of pleasant flashes of light 
and sparkles, a complete ego loss, and apparitions of faces. 
The dosage of DPT, for oral administration, is 100-250 mg 
and the duration of the psychoactive effects varies from 2 to 
4 hours. 
 Diisopropyl-tryptamine (DiPT) is a synthetic 
hallucinogen, structurally related to dimethyl-tryptamine, 
but, unlike DMT, which produces short term visual 
hallucinations, DiPT causes auditory distortions [36]. DiPT 
presents a similar molecular mechanism of action as other 
hallucinogens. It is an agonist at 5HT2A receptors and a 
partial agonist at 5HT1A receptors [37], but 5-HT1A activity 
“is not thought to be necessary for hallucinogenic effects” 
[38]. Furthermore, DiPT blocks the serotonin uptake and it 
has little interaction with dopamine or norepinephrine 
transporters [16].  
 Effective dosage, orally administered, ranges from 50 to 
100 mg [39] and the hallucinogenic effects continue until 6-8 
hours.  
4-POSITION MODIFIED TRYPTAMINES 
 Psilocin (4-OH-DMT) can be assumed “as the prototypical 
agent of the 4-position modified tryptamines” [15]. It is 
obtained by dephosphorylation in the body of psilocybin 
found in hallucinogenic mushrooms of the species Psilocybe 
and Stropharia. In P. cubensis, psilocybin percentage varies 
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from 0.2% to 0.4% of the dry weight [40], while psilocin is 
only present in trace amounts. After ingestion, psilocybin 
undergoes rapid hydrolysis of the phosphate groups by the 
alkaline phosphatase and then turns into its active metabolite 
psilocin, representing the active drug of abuse [41]. After  
the ingestion of Psylocibe ‘Magic mushrooms’, the 
hallucinogenic effects arise within the first 2 hours and then 
decrease in the subsequent 3-4 hours to disappear within 4-8 
hours. The threshold of intoxication is reached after the 
intake of 40 µg psilocybin/kg body weight; “ typically  1–2 g 
of dried mushroom is ingested”, which yields from 2 to 8 mg 
of psilocybin [42]. “Pharmacokinetic studies of psilocybin in 
humans have shown” that, after “the rapid dephosphorylation 
of psilocybin to psilocin”, there is a conversion in plasma  
of “the psilocin into 4-hydroxy-tryptophole (4HT) and  
4-hydroxyindole-3-acetic acid (4HIAA)” [43]. Grieshaber 
showed that psilocin undergoes conjugation with glucuronic 
acid in the liver and it can be found in the urine as the 
psilocin-glucuronide conjugate [43]. Psilocin is a partial 
5HT2a agonist [14], but it is also agonistic at other serotonin 
receptors, with little dopaminergic or noradrenergic action: 
these activities explain the onset of sympathetic stimulations, 
such as tachycardia and hypertension, along with those of the 
predominant hallucinogenic effects [44]. Psilocybin is orally 
active, with effective doses in the range of 6–20 mg. The 
onset of action is typically 20–40 min, peaked after another 
60–90 min, lasting for another 60–120 min [45].  
 The synthetic 4-substituted tryptamines include 4-
hydroxy-N,N-diethyltryptamine (4-HO-DET), 4-hydroxy-
N,N-diisopropyltryptamine (4-HO-DiPT), 4-hydroxy-N-
isopropyl,N-methyltryptamine (4-HO-MiPT) and their 
acetic acid derivatives (for example, 4-acetoxy-N,N-
diethyltryptamine and 4-acetoxy-N,N-diisopropyltrypt- 
amine): all these compounds, according to users [46], seem 
to have similar actions to psilocin, but very little scientific 
information about their properties is available. 
5 POSITION MODIFIED TRYPTAMINES 
 Bufotenine (Fig. 5), or 5-OH-dimethyltryptamine (5-
OH-DMT), is an N-alkylated derivative of serotonin and it 
was first synthesized by Wieland in 1934 [47]: it can be 
isolated from plants Piptadenia peregrina and P. macrocarpa 
(Mimosaceae), the mushrooms Amanita (spp) and from the 
skin glands of toads (Bufo spp.) [48]. Fuller, studying the 
metabolism, the tissue distribution and the effects of 5-OH-
DMT on rats, showed that, after injection in the animals, it 
was present in highest concentration in lung and in heart 
rather than in brain: this, probably, means that it does  
not cross well the blood-brain barrier, just as serotonin [49]. 
In tissues studies, he found that bufotenine was rapidly 
eliminated, disappearing within 8 hours, after reaching  
peak concentrations at 1 hour. Moreover, the large increases 
of 5-hydroxyindoleacetic acid (5HIAA), the endogenous 
metabolite of serotonin, in all tissues suggested that bufotenine 
was metabolized by MAO-A through the pathway of oxidative 
deamination. 
 Ott, published the results of his human self-experiments 
with bufotenine: he self administered bufotenine as free 
base, via intranasal (5–100 mg), sublingually (50 mg), 
intrarectally (30 mg), pulmonary (as inhaled vapor, in a 
dosage of 2–8 mg) and orally (100 mg). These experiments 
were done by way of “pharmacological modeling of diverse 
South American shamanic inebriants, prepared from seeds of 
Anadenanthera peregrina and Anadenanthera colubrina”. 
For each route of self-administration, Ott reported the  
onset of several psychoactive effects, in relation to the 
dosage.  
 Intranasal administration (nine bioassays from 5 to 100 
mg): he reported the visionary threshold at 40 mg; the range 
from 5 to 30 mg caused the onset of psychoactive effects 
at all doses, “with closed-eye luminosity and scintillation 
commencing at 20 mg”. He recorded that at 5 minutes after 
the 40 mg administration, he felt the onset of tinnitus; 
at 25 minutes he felt the body effects typical of the 
intakes of tryptamines; the peak arrived between 35 
and 40 minutes and all the psychoactive sensations 
vanished after 90 minutes. He noted also that he did not 
feel discomfort or side-effect. 
 Sublingual administration (50 mg): he reported that 
“free base bufotenin taken sublingually was found to be 
similar to intranasal use”, for what concerned “the potency, 
duration, and psychedelic action”. 
 Intrarectal administration (30 mg): he reported mild 
physical effects that developed quickly and that lasted roughly 
an hour. He felt psychotropic effects, like scintillations with 
closed eyes, only when he co-administered harmaline with 
bufotenine suppository. 
 Administration via inhaling vapor (2-8 mg): he inhaled 
2, 4, 6 and 8 mg of bufotenine. All doses were decidedly 
psychoactives, increasing in potency proportionally to 
dosage. The peaks were attained after four to five minutes 
with a gradual diminution of the effects for an hour. 
 Oral administration (100 mg): he reported that 100 mg 
dose was most decidedly psychoactive. Tinnitus manifested 
at 20 minutes, the peak was reached at one hour and 30 
minutes “with all the classic tryptaminic bodily sensations 
and mild psychoptic effects, but absent colored patterns” 
[50]. 
 The 5-substituted tryptamines, also include 5-methoxy- 
α-methyltryptamine (5-MeO-AMT), 5-methoxy-N,N-
dimethyltryptamine (5-MeO-DMT), 5-methoxy-N,N-
diisopropyltryptamine (5-MeO-DiPT, “Foxy Methoxy”), 5-
methoxy-N,N-methylisopropyltryptamine (5-MeO-MiPT): 
these compounds inhibit monoamine re-uptake, but they 
have few effects on monoamine release.  
 5-methoxy-α-methyltryptamine (5-MeO-AMT) is a 
psychedelic tryptamine which presents structural similarities 
 
Fig. (5). 5-hydroxy-N,N-dimethyltryptamine. 
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to the amphetamines: because of these characteristics, 5-
MeO-AMT was occasionally sold under the guise of LSD, as 
emerges from the reports of Drug Enforcement Agency 
(DEA) about seizures of sugar cube, or blotters LSD-style, 
containing this tryptamine [51]. Its mechanism of action is 
characterized by binding to 5-HT1A and 5-HT2A receptors 
[52, 53] it also inhibits the monoamines reuptake and 
increases their release in brain synaptosomes at micromolar 
concentrations [16]. 5-MeO-AMT is orally administered in a 
range of 2.5-4.5 mg and the duration of the effects reported 
is about 12-18 hours. If misrepresented as LSD, 5-MeO-
AMT can be very harmful or even fatal: in fact, incorrect or 
excessive administration of the substance, mistaken for LSD, 
has been the cause of several hospital admissions [54] or 
sudden deaths [55].  
 It is likely that the danger related to 5-MeO-AMT 
assumption is due to its sympathomimetic effects, that 
include, as side effects, cardiac arrhythmia and seizure.  
 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is 
a naturally occurring psychoactive indolealkylamine 
substance, closely related to DMT and bufotenine. It was 
initially isolated from the bark of Dictyoloma incanescens 
[56], but it was found also in the venom of Colorado River 
Bufo alvarius, secreted by parotoid and tibial glands. This 
compound is a potent, fast acting hallucinogen [57], producing 
psychedelic effects, with a short duration in humans: it has 
high affinity for the 5-HT1A serotonin receptor, causing many 
physiological and behavioral changes. It can be administered 
by different routes, as reported in the Table 1. 
 
Table 1. Routes and dosages of administration of 5-MeO-
DMT in humans from Shen [57]. 
5-MeO-DMT 
Routes of Administration Dosage (mg) 
Inhalation 6 - 20 
Intravenous injection 0.7 - 3.1 
Sublingual or Intranasal insufflation 10 
Oral (with MAOI) 30 
 
 5-MeO-DMT is mainly metabolized by monoamine 
oxidase A (MAO-A) through a deamination pathway, and it 
is O-demethylated by cytochrome P450 (CYP2D6) enzyme 
[57], producing, as active metabolite, bufotenine, which 
binds 5-HT2A receptor with higher affinity than 5-MeO-DMT 
itself.  
 For this reason, to produce a prolonged hallucinogen 
effect when orally administered, 5-MeO-DMT requires the 
concomitant use of a MAOI, such as harmaline. This co-
administration could lead to an hyperserotonergic syndrome 
because of the agonistic activity of these two substances on 
the serotoninergic system: in fact, MAOI activity causes an 
increasing exposure to the parent drug (5-MeO-DMT) and to 
the active metabolite (bufotenine), originating a possible 
fatal toxicity (Fig. 6). 
 In his self-experiments, Ott, revealed that after 
insufflation [58], 5-MeO-DMT caused visionary and 
auditory changes, with a distortion of the perception of time. 
The onset of these effects was after 3-4 minutes from the 
administration, the peak was reached after about 35-40 
minutes and they lasting until 60-70 minutes. He demonstrated 
also that oral ingestion compared with intranasal or 
sublingual ingestion of 30-35 mg of 5-MeO-DMT produced 
limited effects or could produce no psychoactive effects  
at all. 
 5-methoxy-diisopropyltryptamine (5-MeO-DiPT), or 
“Foxy Methoxy”, produced by the addition of two isopropyl 
groups to the terminal nitrogen of the aminoethyl group, and 
methoxylation of the 5-position of the indole ring, is a 
synthetic designer drug which was first synthesized and 
described by Shulgin.  
 Sogawa “investigated the actions of 5-MeO-DiPT against 
monoamine neurotransmitter transporters, using COS-7 cells 
heterologously expressing these transporters and rat brain 
synaptosomes”, and demonstrated that “5-MeO-DiPT acts  
as a competitive serotonin transporter (SERT) inhibitor and 
has an inability to cause reverse transport, underlying its 
serotonergic actions” [59]. Agonistic activity at serotonin 
receptors could lead to permanent damages to serotonergic 
neurons with neuropsychiatric implications [60]. Fantegrossi 
reported also that “5-MeO-DiPT had affinity for receptors 
relevant to hallucinogenic effects” observed in vivo, and that 
the psychotropic activity of 5-MeO-DiPT might therefore be 
caused by its association with post-synaptic 5-HT receptors 
[61]. In human biological samples, such as blood and urine, 
5-MeO-DiPT is mainly metabolized in 5-hydroxy-N,N-
diisopropyltryptamine (5-OH-DiPT) and in 5-methoxy-N-
isopropyltryptamine (5-MeO-NiPT) [62]. 5-MeO-DiPT is 
orally active, and dosages between 6–12 mg are reported by 
Shulgin, but it can be also smoked, or snorted. Its onset of 
action is in 20 to 30 minutes, and its effects last from 3 to 6 
hours. The users experienced euphoria, disinhibition, increased 
sociability, visual and auditory hallucinations, feeling of love 
but also less desiderable effects like myoclonus, restlessness, 
insomnia and anxiety, as well as emotional distress like 
nausea, vomiting and diarrhea.  
 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT)  
was first synthesized by Shulgin and although information 
on this tryptamine was available since 2004, “its use as 
hallucinogenic drug has been reported only occasionally in 
on-line fora” [10]. According to the European Database on 
New Drugs (EDND), it was first sequestered as two grey 
tablets, in 2006 at Helsinki airport [10]. There is little 
scientific literature on this tryptamine: Nonaka showed that 
5-MeO-DALT seemed to support G protein activation via 
serotonin 5-HT1 receptor with experiments on rat brains [63]. 
Moreover, it did not show effect on dopamine, serotonin and 
norepinephrine re-uptake and presented a slight monoamine-
releasing activity [16]. 5-MeO-DALT is mainly found in 
powder form that is taken orally or nasally. The range of 
doses and effects is unusually broad. Shulgin reported 
dosages for oral administration from 12 to 25 mg: users 
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reported that the onset of its effects was within 15 minutes, 
the peak was reached in 30 minutes and the main effects 
lasted for 2-4 hours, including euphoria, visual hallucinations, 
walking difficulties, and ‘out of body’ experiences. 
 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-
MiPT) is an analogue of the more popular drug 5-MeO-DiPT 
(“Foxy”) and, for this reason, it is nicknamed "Moxy".  
 With regard to its mechanism of action, Fantegrossi 
demonstrated that 5-MeO-MiPT, as the 5-MeO-DiPT, 
suppressed the re-uptake of 5-HT and the re-uptake of 
dopamine and norepinephrine. It showed little dopamine,  
5-HT or norepinephrine releasing activity [61].  
 5-MeO-MiPT can be smoked or orally administered. The 
dosage for oral use is from 4 to 6 mg and the duration of the 
effects is from 4 to 6 hours, while if it is smoked the dosage 
is 12-20 mg. The onset of the psychoactive sensations, after 
oral assumption, is from 15 to 20 minutes, the peak is 
reached from 45 to 60 minutes and the return to normality is 
registered after about 10 hours. If it is smoked, the onset is 
immediate, the duration of the effects is from 2 to 5 hours 
and symptoms disappear after about 2-4 hours. The effects 
reported by the users including euphoria, increased tactile 
sensations, relaxation, visual distortions and difficulty in 
sleeping [64].  
ERGOLINES: HAWAIIAN BABY WOODROSE AND 
MORNING GLORY SEEDS 
 Ergine, or lysergic acid amide (LSA), is an alkaloid of 
the ergoline family closely related to LSD, found in the 
seeds of Argyreia nervosa (Hawaiian baby woodrose) and 
Ipomoea violacea (Morning Glories).  
 Hallucinogenic activity of LSA occurs with 4-10 seeds of 
Argyreia nervosa or with 150–200 seeds (3–6 g) of Ipomoea 
violacea: seeds could be crushed or eaten whole, or also 
drunk as an extract, after soaking in water [42]. The onset of 
the hallucinatory effects, after ingestion of Hawaiian  
Baby Woodrose, is from 20 to 40 minutes and their total 
duration is from 5 to 8 hours: the plateau is reached after 4-6 
hours and the return to normality is after 1-2 hours from the 
plateau. The principal sensations reported by the users 
include relaxations, mild euphoria, feelings similar to 
alcohol intoxication [65], psychedelic visual effects such as 
enhanced colors, but also anxiety, nausea, confusion and 
paranoia [66]. However, as regards to the assumption of the 
Morning Glory seeds, the onset of the hallucinatory effects is 
from 30 to 180 minutes and they last for 4 to 10 hours. The 
users reported that they return to normality after about 24 
hours [67]. 
 Morning Glory seeds assumption can produce a 
heightened sense of awareness of colors, textures and 
sounds: the users reported also a diminished sense of reality, 
an increased sense of suggestibility, but also a sense of 
anxiety and panic, nausea, vomiting, and psychotic episodes 
[68]. 
EFFECTS DUE TO ASSUMPTION OF TRYPTAMINES 
REPORTED ON INTERNET 
 The information regarding the effects of tryptamines 
reported in this paragraph, is collected from websites, so 
these effects are exclusively the result of personal experiences 
of authors and do not follow the use of the scientific method. 
They are reported because Internet is probably one of  
the most effective sources of timely information for any 
specialist or organization interested in the subject. 
 The tryptamines users are not always aware of what  
they have purchased and of its chemical constituents, and 
there are many risks associated with the possibility of 
overdose, repeated administration and incorrect route of 
administration. In this section, we are going to report the 
main effects connected with the use of tryptamines, included 
the one reported as “positive” by authors.  
 
Fig. (6). Agonistic action of harmaline, 5-MeO-DMT and bufotenine on serotonergic system inducing hyperserotonergic effects. 
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 The routes of administration of the various tryptamines 
are one of the key factors that need to be evaluated: some 
can be taken orally or intramuscularly or intravenously, or 
can be smoked or inhaled, showing an increased of 
hallucinogenic sensations, especially in relation to dose  
and repeated-dose toxicity due to a delayed onset of 
phenomenology. 
ASSUMPTION OF RING UNSUBSTITUTED 
COMPOUNDS  
 Ring unsubstituted compounds such as α-methyltryptamine 
(AMT) and α-ethyltryptamine (AET) have stimulant properties 
as well as hallucinatory effects [18]. AET is described as 
having psychoactive properties similar to MDMA. Tables 2 
and 3 summarize AMT and AET experiences as reported on 
www.erowid.org [69, 70].  
 N,N-dimethyltryptamine (DMT), offers an insight  
into the psychoactive properties of other tryptamines:  
it is not active after oral ingestion due to extensive first  
pass metabolism via MAO, so it is generally assumed 
intramuscularly, subcutaneously, intravenously, or even be 
smoked. In Table 4 are summarized DMT experiences in 
relationship with the route of administration reported on the 
website www.erowid.org [71].  
Table 2. The principal routes of administration of AMT and its correlated experiences as reported on www.erowid.org [69]. 
AMT EXPERIENCES 
Route of Administration Dosage Effects (12-16 Hours) 
Oral (15-30 mg) with 15 mg 
 
with 30 mg 
 
with 100 mg 
"I got a strong psychedelic experience that lasted about twelve hours, but an unexpected relief from my 
chronic depression that lasted for four days." 
"It felt a little like speed, strong speed. Yet I found myself yawning and in sort of a dreaminess state and 
quite lethargic. It lasted a long time." 
"There was pupillary dilation, jaw clenching, tachycardia and vomiting. Too much. But I really liked this 
compound at lower dosages." 
Smoked (5-20 mg) with 5 mg 
 
with 20 mg 
"Qualitatively it was milder and less intense than mushrooms, but much longer lived. Not complex, but just 
a lot of very good spirit, energetic feeling, enhanced colors, attractive rhythms in music. Party stuff." 
"I inhaled several hits from my vaporizer and sat back. I felt head-pressure and uneasiness, then suddenly I 
became very fast. My mind was moving fast, and my body was speeding along with it in an unconscious 
way. Several hours into it, I began to notice more of a psychedelic effect beginning to manifest. It seemed 
as if the speedy part was becoming less predominant and the psychedelic visual effects were starting to kick 
in. I went back to my room to watch the distinctive waves of a soft red/orange visuals They were similar to 
colors of LSD. It gradually increased to a level of intensity, and after several more hours it was clear that I 
had reached the plateau. Feeling fairly tired and ready for bed, I decided to call it a night. Quite to my 
surprise, when I awoke four hours later I was at the same level as when I went to sleep. Gradually over the 
next day I returned to baseline and I was left feeling quite euphoric with a pleasant afterglow." 
 
Table 3. AET experiences at different dosages after oral administration as reported on www.erowid.org [70]. 
AET EXPERIENCES 
Route of Administration Dosage Effects (6-8 Hours) 
Oral (100-150 mg) with 100 mg 
 
with 150 mg 
 
 
 
 
 
with 160 mg 
"A nearly imperceptible feeling of well-being and pleasure was noted about 80 minutes later, and seemed 
completely gone at three hours.” 
"My dosage level was the highest of the group, but to my surprise, it had almost no effect whatsoever. A 
plus-one, if anything. After the peak, as I was slowly coming down, I was aware of feeling slightly depressed. 
This state continued until I achieved baseline, but was not severe enough to prevent me from participating in 
the general good spirits of the group. There is a real possibility that my weekly use of MDMA for writing 
might have built up a tolerance to the stimulation of this material. I think that that may be close to the 
answer. Would I take it again? Not with much enthusiasm. It didn't give enough exciting rewards." 
"A strong feeling of being-at-peace was evident in an hour, although there was some concentration required 
to do things in a coordinated way. I wouldn't want to drive a car. There seemed to be very easy drifting of 
thoughts but no visuals or sensory distortions. There were no GI disturbances anywhere along the line except 
for some loose stools the next morning. Appetite was slightly depressed, but food tasted very good. A very slight 
tremor could be detected in the fingers around the peak of the experience. There was a desire to talk with 
friends somewhat reminiscent of MDMA; I am sure that this drug could be quite a social-enhancing material. 
The effects wore off gradually and were essentially gone by the six hour point. Sleep was unaffected, however 
the next morning there was a slight feeling of dullness and possibly hang-over which quickly wore off." 
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 DMT produces, in recreational doses, sudden onset of 
intense visual hallucinations [19, 72, 73]. Sympathomimetic 
effects such as dilated pupils, tachycardia and hypertension 
are more prominent at lower doses: some users report that 
the experience is more intense than that following LSD 
exposure [15].  
 Unlike DMT, other unsubstituted tryptamines are orally 
active. Smoking and nasal insufflations are also common 
methods of administration. Visual hallucinations are 
universal reported as “positive” effects by users [74]. 
General effects reported as “positive” on www.erowid.org 
by users of unsubstituted tryptamines, that are active after 
ingestion, include: ‘rushing’ sensation, both opened and 
closed eyes ‘pleasant’ visual hallucinations, increased mood, 
energy, libido, concentration and empathogenic qualities 
[75]. These effects are collected in Table 5. 
Table 4. Routes of administration of DMT and its principal psychoactive experiences as reported on www.erowid.org [71]. 
DMT EXPERIENCES 
Route of Administration Dosage Effects (up to 1 Hour) 
Oral (>350 mg) up to 350 mg “Completely without effect either physiological or psychological” 
Intramuscularly (60-100 mg) with 80 mg “My perceptual distortions were visual in nature and with my eyes closed I could see colored patterns, 
primarily geometrical patterns moving very fast, having sometimes very deep emotional content and 
connotation. My blood pressure went up and my pupils were dilated.” 
Subcutaneously (60-100 mg) 
(via the buccal mucosa) 
with 100 mg "Numbness at the site, but no central effects.” 
Intravenously (4-30 mg) with 30 mg "I was hit harder that I had ever been when smoking the stuff. The onset was similar,  
but the euphoria was less." 
Smoked (60-100 mg) with 100 mg "As I exhaled I became terribly afraid, my heart very rapid and strong, palms sweating. A terrible sense 
of dread and doom filled me - I knew what was happening, I knew I couldn't stop it, but it was so 
devastating; I was being destroyed - all that was familiar, all reference points, all identity - all viciously 
shattered in a few seconds. I couldn't even mourn the loss - there was no one left to do the mourning. 
Up, up, out, out, eyes closed, I am at the speed of light, expanding, expanding, expanding, faster and 
faster until I have become so large that I no longer exist - my speed is so great that everything has 
come to a stop - here I gaze upon the entire universe."  
 
Table 5. Unsubstituted simple tryptamines effects as reported on www.erowid.org [75]. 
Unsubstituted Tryptamine Dosage 
(mg) 
Duration of Action 
(Oral 
Administration) 
“Positive” Effects 
DET 
(N,N-diethyltryptamine) 
50-100 2-4 hours With 44 mg: "I was in a public place, and might have had to interact with someone 
at any moment, which probably accounted for a grim paranoia and wish to retreat. I 
had my full effect in just over an hour, with almost no visual or physical properties, 
but a crashing fear of interacting. Good sleep, no residues." 
With 150 mg: "There was a slow onset. It was more than an hour before something 
started. I was heading toward an appointment, and walked right past the meeting 
place. I was unable to concentrate on just where I was and where I was hoping to 
go. With enormous effort I located my appointment coordinates but the sidewalk 
was doing funny things and I again managed to miss my target. I sat down to try to 
manage things, but I couldn't." 
DPT 
(N,N-dipropyltryptamine) 
100-250 2-4 hours With 200 mg: "This started sooner and was a lot stronger than I had expected. I had 
trouble talking and I felt very uncomfortable. I think physically I was in a chair but I 
was on a kind of mountain surrounded by clouds. And the clouds talked to me." 
DiPT  
(N,N-diisopropyltryptamine) 
25-100 6-8 hours With 50 mg: "Everything was auditory, and I can only describe it with a '!'" 
With 100 mg: "Nothing until 35 minutes when a definite change in hearing was 
observed. There was a decrease in high frequency acuity with an unusual tonal shift 
of all frequencies to a lower pitch. Voices sounded very similar to a single side-
band radio signal which had been mistuned to the low side of the center frequency. 
No effects were noted with respect to clarity of speech, and both comprehension 
and interpretation were normal. There were no changes in vision, taste, smell, 
appetite, vital signs, or motor coordination. The effects began to fade at four hours 
post ingestion, and were completely gone at eight hours.” 
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ASSUMPTION OF 4-POSITION MODIFIED 
TRYPTAMINES 
 Synthetic 4-substituted tryptamines are orally active and 
they seem to produce similar effects to those mediated by 
psilocin. General effects include: increased laughing, intense 
visual hallucinations, ‘rushing’ sensation, euphoria, increased 
libido, enhanced tactile sensations, increased concentration 
and a feeling of warmth and inner peace [76]. Dosage and 
effects of most common synthetic 4-substituted tryptamines 
on www.erowid.org, are reported in Table 6 [75]. 
ASSUMPTION OF 5-POSITION MODIFIED 
TRYPTAMINES 
 The 5-substituted tryptamines are more powerful than the 
unsubstituted molecules, but clinical effects reported are 
similar among them. Effects reported as “positive” by users 
of 5-substituted tryptamines include [58]: euphoria, an 
increasing of energy, libido, concentration and sociability, 
and a reduction in fear and anxiety [57]. Table 7 represents a 
summary of the reported effects of the personal experiences 
of the users of some 5-substituted simple tryptamines by 
Alexander and Ann Shulgin [75]. 
 Internet drug user fora, including Erowid, published also 
reports of the adverse effects following to tryptamine 
administration. The accuracy of reports is limited by possible 
user bias, difficulty in ascertaining the identity and amount 
of the substance exposure and the possibility of co-
ingestants. General user reports of adverse or unwanted 
effects of unsubstituted tryptamines include: restlessness, 
yawning, anxiety, tension, nausea, vomiting, palpitations, 
muscle pain, bruxism, headache, frightening or distressing 
hallucinations, overwhelming fear (DMT), abdominal 
discomfort, nasal irritation when insufflated and respiratory 
discomfort or distress when inhaled [76, 78]. Moreover, the 
incorrect or excessive administration of 5-MeO-AMT, 
mistaken for LSD, has been correlated with several hospital 
admissions [54] or sudden deaths [55]. In the Table 8 are 
summarized the main adverse effects reported by users in 
relationship with the tryptamine derivatives assumed. 
TRYPTAMINES EFFECTS AND INTOXICATIONS: 
CASE REPORTS FROM EMERGENCY ROOMS AND 
CORONERS’ ACTIVITIES 
 Gathering data on the use of these new psychoactive 
substances it is very difficult, since they are not collected in 
a systematic way and often these information come from 
unverified sources (drug-related fora or websites). So the 
only evidences that have an epidemiological significance 
derive from arrests and seizures by law enforcement 
agencies [14], from the numbers of enquires to poisons 
centers, from the reports of the emergency departments or 
from admissions to hospital. Unfortunately, the limited 
number of these official reports may underestimate the true 
extent of the problem [80]: statistics on deaths may also be 
available, but often these publications do not provide 
information on toxicity or mode of action of these substances 
as completely lacks the analytical confirmation of the agents 
involved, and the causes of death are ascertained or through 
the testimonies of family members and friends, or after the 
discovery of the substance at home or in the clothes of the 
deceased. Nevertheless, in scientific literature are reported a 
consistent number of cases of acute poisoning due to the 
increasingly widespread use of these new psychoactive 
substances: many of these are the result of emergency room 
experience. As the amount of tryptamines necessary to cause 
psychotropic effects is minimal, and the interval of 
occurrence of effects is rather delayed [39], there is a risk of 
inappropriate new assumptions, that could lead to poisoning 
or overdose. 
 Holstege reported the case of poisoning of a college 
student (male, 21 years old) came in E.D. after ingestion  
of 270 mg of AMT purchased on the internet [81]. The 
subject reported that he had used the same AMT lot of 
different times for its psychedelic properties, and to have 
miscalculated the last dose, ingesting a dose about 10 times 
higher than the previous. After an hour of ingestion 
presented hypertension (BP 183/93 mmHg, heart rate of 52 
bpm), with normal respiratory rate and apyrexia. The patient 
was awake, hyper-alert, oriented with mydriasis (10 mm 
diameter), moderate tremor, delay in response times, restless, 
in exaggerated startle reaction and visual hallucinations. 
After 10 hours the symptoms begun to resolve. The diagnostic 
tests were normal, except for a slight value hypokalemia. He 
was discharged without complications. 
 Long reported during the EAPCCT XXIII International 
Congress the case of a patient (male, 17 years) arrived at the 
hospital with sympathomimetic effects after ingestion of 
AMT. The subject was found almost completely naked, while 
ran, and cried, and did not have previous medical or psychiatric 
history. He presented tachycardia (160 beats/min), extreme 
sweating (with temperature 37.28°C), and mydriatic pupils 
of 6-7 mm and reactive. The rest of the physical examination 
appeared normal, and the patient was immediately sedated 
with 6 mg lorazepam administrating by intramuscular route. 
Routine laboratory tests were normal, as well as the analysis 
of the cerebrospinal fluid and brain scan. Analysis of urine 
were negative for cannabinoids, cocaine, amphetamines, and 
phencyclidine. The day after the subject indicated the 
assumption of AMT, purchased on the Internet with the 
instruction for insufflation of 100 mg. The patient, however, 
reported that he had ingested the powder rather than take it 
by inhalation, with onset of symptoms after 15 min. HPLC 
analysis of the urine has confirmed the presence of the AMT 
and the absence of cocaine, phencyclidine, and amphetamines. 
The authors conclude that the intake of AMT involves rapid 
heartbeat, sweating, agitation and hallucinations and suggest 
supportive therapy, including sedation with benzodiazepines 
[82]. 
 A case of intoxication after ingesting an unknown 
amount of DPT is reported in a 19 years old female by 
Dailey: when she arrived in E.D. presented hallucinations, 
extreme agitation and tachycardia (200 bpm). Clinicians 
administered 3 mg of lorazepam to resolve the state of 
agitation. Toxicological analysis did not reveal positivity for 
DPT: the assumption of DPT was ascertained only for the 
presence with the patient, of a vial with a label bearing the 
inscription “for research purposes only” [83].  
 Brush, reported a case of an adolescent (17 years old 
male) whose use of the Internet to obtain drug information 
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Table 6. Dosage and effects of most common synthetic 4-substituted tryptamines as reported on www.erowid.org [75]. 
4-substituted Tryptamines Dosage  
(mg) 
Duration of Action 
(Oral Administration) 
“Positive” Effects 
4-HO-MET 
(4-hydroxy-N-methyl-N-
ethyltryptamine) 
10-20 4-6 hours With 20 mg: "Qualitatively a lot like psilocin. I started within the first half-
hour, and at the max, I felt the same alteration of color and form, and times, 
sound was felt. As with psilocin, the experience was wave-like, with an 
alteration of effects between near-normal perception at one minute, only to 
be swept up in a swirl of altered concept the next minute."  
4-HO-DET 
(4-hydroxy-N,N-diethyltryptamine) 
10-25 4-6 hours with 15 mg indolol: "Time really slowed down, with sparkly-ness, 
interesting, and yet there was a touch of sadness. The intense visuals held 
the scene, and there was the compulsion to talk and to interact and to share 
stuff, but the erotic was not to be found. I slept OK but there was something 
uncomfortable at a deep level. Am OK."  
with 15 mg phosphate ester: "The feelings I experienced could best be 
described as cosmic tenderness, infinite love, penetrating peace, eternal 
blessing and unconditional acceptance on one hand and, on the other, as 
unspeakable awe, overflowing joy, primeval humility, inexpressible 
gratitude and boundless devotion. Yet, all of these words are hopelessly 
inadequate and can do little more than meekly point toward the genuine, 
inexpressible feelings actually experienced." 
With 20 mg acetate ester: "A strange mixture of things at an hour, 
sedation, jaw-tightening, and a generalized body tremor. The light from the 
fireplace gave me bursts of color. Music allowed me to drift with my 
thoughts. Anorexia was intense. Four hours into it I was fine on the 
telephone to a friend who knew nothing about the day." 
4-HO-DiPT 
(4-hydroxy-N,N-
diisopropyltryptamine) 
15-20 2-3 hours With 15 mg: "There was an alerting, noisy and nice, in 30 minutes. Nice 
friendly place. Perhaps some light tension, like a chill, maybe my body 
temperature response is confused. At the two hour point I am substantially 
out of the experience. Short, intense experience, basically enjoyable."  
With 20 mg: “Early signs noted at 15-20 minutes which include mild 
sensation of central stimulation, 'loosening' of muscles in arms, legs, and 
neck. Mild distortion of objects and slight color effects, typically 'rainbow 
halos' around objects. Plateau reached in 20 minutes. 2.0 hours, mild effects. 
2.5 hours, nearly normal. Mild but entirely pleasant experience with rather 
abrupt termination of effects."  
4-HO-MiPT 
(4-hydroxy-N-isopropyl-N-
methyltryptamine) 
12-25 4-6 hours With 12 mg: "The first awareness was unmistakable at twenty minutes, and 
from there it was a rapid and noisy development ending at about an hour. 
But this lasted for only another 40 minutes, and then dropped off quite 
rapidly. The erotic was excellent, but there were few visuals and I had 
difficulty connecting fantasy to music. Good appetite afterwards, and I had 
no trouble getting to sleep." 
With 30 mg acetate ester: "It was as if I had downed a few martinis in a 
hurry - except that there were eye-closed visuals in a lot of different colors, 
especially metallic greens. I had jaw clenching and a body tremor, 
reminding me of ecstasy except is was not in any way stimulated. I listened 
to music in front of a fireplace in a darkened room and I saw bright colorful 
unstructured patterns. Seven hours and I fell into an easy sleep and was fine 
the next day."  
4-MeO-MiPT 
(N-isopropyl-4-methoxy-N-
methyltryptamine) 
20-30 4-6 hours With 17 mg: "I am aware of this at 40 minutes, and was in a very light but 
not very well defined place for about two hours. It was neither good nor 
bad. It kind of drifted away and I was not sure when I regained baseline." 
With 26 mg: "This is my first try with this drug, ever. First indications of 
effects in twenty minutes. Quiet onset, no remarkable visuals, in fact no 
particular visuals at all. To a plus two within about ten or fifteen minutes 
more. Body is comfortable, mind-set pretty much unchanged from baseline. 
No euphoria, no insights. But also, no discomfort. Erotic was extremely 
successful. Still no visuals but seemed to be a soft plus three. Music fine. 
Hard to define exactly how we knew we were in an altered state, because of 
the lack of visual clues. Body aware more than mind. Would like to explore 
this further."  
Recreational Use, Analysis and Toxicity of Tryptamines Current Neuropharmacology, 2015, Vol. 13, No. 1    37 
Table 7. Experiences of the users of some 5-substituted simple tryptamines reported by Alexander and Ann Shulgin [75]. 
5-substituted 
Tryptamines 
Dosage  
(mg) 
Duration  
of Action 
“Positive” Effects 
5-MeO-DET 
(N,N-diethyl-5-
methoxytryptamine) 
1-3 
(oral administration) 
3-4 hours With 3 mg: "It hit in a half hour, and the thought that came to mind was the phrase from 
my days at college, "Boy, I really felt that drink!" I may be sloppy, but let me explore the 
sexual. Wow. I may be spacey in the head, but my body knows where it is at. The next 
day was normal. I don't think I want to do this again." 
5-MeO-DMT 
(N,N-dimethyl-5-
methoxytryptamine) 
6-20 smoked 
2-3 i.v. 
1-2 hours With 6 mg, smoked: "I felt it in a minute - not really light head, but the head feels close 
to the lower parts of the body - close to the ground - knees weak - distinct shakes. I 
peaked at 2 or three minutes. Slight nausea on the drop-off - I am glad I had not eaten 
anything. It's greatest contribution might be to provide a subject the vocabulary of an 
altered state of consciousness so that, with interesting and constructive drugs, these 
effects will be familiar, and thus not distractions."  
With perhaps 20 mg, smoked: "This is a very strong hallucinogen. A twenty minute 
experience. The 5-MeO-DMT was relaxed, a kind of cosmic consciousness type of 
experience. I broke into a space similar to DMT but it was more like receiving grace. I 
felt a little shaky (tremor-like) coming down." 
With 35 mg, orally: "No activity." 
With 2.3 mg, i.v.: " I thought I was an ocean. I don't remember where I first lost 
continuity of consciousness but I remember being aware of the sounds I was making 
apparently some time after I began vocalizing. Around the time I thought to change these 
sounds as I pleased, I also noted with brief wonder that the sound was continuous, not 
changed by my breathing. I sang my way back." 
5-OH-DMT 
(5-hydroxy-N,N-
dimethyltryptamine) 
8-16 
(i.v. administration) 
1-2 hours With 8 mg, i.v., over a 3 minute period: "I became lightheaded as soon as the injection 
started, and then my face turned purple and I became nauseated and I felt I couldn't 
breathe. I see white, straight lines with a black background. I can't trace a pattern. Now 
there are red, green and yellow dots, very bright like they were made out of fluorescent 
cloth, moving like blood cells through capillaries, weaving in and out of the white lines." 
With 16 mg, i.v., over a 3 minute period: "Almost immediately I felt a burning 
sensation in the roof of my mouth and I felt a tingling all over my body. My face turned 
purple, and my chest feels crushed. Everything has a yellow haze, and I was sweating 
heavily and I vomited. Words can't come. My mind feels crowded. When I start on a 
thought, another one comes along and clashes with it. I can't express myself clearly. I am 
here and not here. It has now been forty minutes and I feel better, but I still feel like I 
would like to walk it off, like a hang-over." 
5-MeO-DiPT 
(N,N-diisopropyl-5-
methoxytryptamine) 
6-12 
(oral administration) 
4-8 hours With 6 mg: "Effects were present in twenty minutes, and I took my portable radio into 
the garden at forty minutes just to pull weeds. Each weed had special significance, and 
my cat Ms. joined me and agreed with me. This is excessively strange. The radio was 
discussing a President Ford fund-raiser, and continued with word sequences such as 
fund, fun, profun, profound, profane, refrain, and on and on. A car drove by with sitar 
music playing on its radio! Why not. And by my hour number three, I am back where I 
started. That was quite a morning."  
With 12 mg: "Awful, awful taste. Quickly aware and in the second half hour I rapidly 
shot up in a very LSD-like manner, without the visuals. Time was quite slowed down 
during this come-on. Erotic world was fantastic, explosive, almost scary. Rapid drop-off, 
and by the fourth hour I am clear of any effects." 
5-MeO-MiPT 
(N-isopropyl-5-
methoxy-N-
methyltryptamine) 
4-6 
(oral administration) 
4-6 hours With 4 mg: “Up very fast. Absolutely no visuals, but over the next two hours an ease of 
interpretive fantasy, almost dream-like, and easy eroticism. Food tasted marvelous, but 
there was no appetite. Easy, normal sleep." 
With 6 mg: "Rapid development to 45 minutes, some shakes, uneven handwriting, and 
hints of time slowing. Extremely erotic. Full plateau at the 2 1/2 hours. point, then a 
graceful and rather rapid drop. Easy, restful sleep. Absolutely no visuals or related 
sensory effects. Very pleasant, music extremely acceptable. " 
5-MeO-DALT [77] 
(N,N-diallyl-5-
methoxytryptamine) 
12-20  2-4 hours With 10 mg: "I am looking at everything through someone's open friendly eyes, not 
mine. I would like to go through life like this if others saw me as OK. I am 10 feet tall, 
my pulse is 72 but uneven, and light-headed is a better describer of where I am than 
psychedelicized." 
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Table 8. Adverse effects related to tryptamine derivatives assumed. 
Tryptamine Adverse Effects 
AMT Nausea, vomiting (particularly common), anxiety, restlessness, muscle tension and palpitations. 
DiPT Ataxia, confusion and inner ear discomfort. 
5-MeO-DiPT Nausea, abdominal discomfort and diarrhoea. 
4-substituted tryptamines Lethargy, fatigue, anxiety, fear, paranoia, frightening hallucinations, intense overwhelming thoughts or visual 
disturbances, diaphoresis, flushing, elevated heart rate, muscle pain, confusion and difficult speaking. 
5-substituted tryptamines Terror, anxiety, fear, paranoia, frightening hallucinations, intense overwhelming experiences, respiratory discomfort or 
distress when inhaled, difficulty integrating experiences into normal life, nausea and vomiting at higher doses, 
headache, fatigue, muscle pain, abdominal discomfort, diarrhoea, minor bruxism. 
5-MeO-DALT Retrograde amnesia with higher doses. 
Lysergic Acid Amide (LSA) Anxiety, nausea, vomiting, abdominal pain, delirium, dizziness, confusion, fear and paranoia [79]. 
 
 
led to severe poisoning from the combination of a monoamine 
oxidase inhibitor, harmaline, and a hallucinogenic tryptamine, 
5-methoxydimethyltryptamine (5-MeO-DMT) [84]. He 
purchased on the Internet some Syrian rue seeds containing 
harmaline, a natural MAOI [76]. After ingestion of seeds, 
smoking 10 mg of 5-MeO-DMT, and insufflation of further 
15-20 mg, his friends found him collapsed, agitated and 
hallucinating. He arrived in E.D. with tachycardia (heart rate 
186 bpm) and hyperpyrexia (40.7°C). He required physical 
restraint and clinicians administered to him 2.5 mg of IV 
lorazepam. This case illustrates the extreme danger of 
simultaneous administration of tryptamine with MAOIs: 
indeed, the concomitant use of harmaline and 5-MeO-DMT 
reduces deamination metabolism of the parent drug, leading 
to a prolonged and increased exposure to 5-MeO-DMT, as 
well as to its active metabolite bufotenine [57].  
 Wilson, reported the case of a 23-year-old man arrived to 
the Emergency Department after ingestion of a 5-MeO-DiPT 
homemade capsule. He did not lament visual nor auditory 
hallucinations, but only sensory distortion such as formication. 
Paranoia symptoms were observed. The patient was put 
under observation and then discharged. Toxicological analysis 
performed in blood and urine with gas chromatography–
mass spectrometry revealed the presence of “Foxy” (5-MeO-
DiPT) in the following concentration 0.14 (serum) and 1.6 
µg/mL (urine), and its metabolite 5-methoxy-indole acetic 
acid was found in urine 0.17 µg/mL [85].  
 The ingestion of “Foxy” was associated with 
rhabdomyolysis and transient acute renal failure: Alatrash 
reported the ingestion of 25 mg of 5-MeO-DiPT in a healthy 
23 years old man who arrived in E.D. presenting an altered 
state of consciousness characterized by hallucinations, 
tachycardia, hypertension and hyperpyrexia. Clinical 
investigations revealed renal impairment, metabolic acidosis 
and rhabdomyolysis. Toxicological analysis performed on a 
urine sample was negative for amphetamines, cannabinoids, 
cocaine, ethanol and barbiturates: the tests, executed in E.D., 
didn’t confirm the presence of 5-MeO-DiPT [86].  
 The ingestion of an unusual dose of “Foxy” in a 19 years 
old man is reported by Smolinske. On arrival, he had 
hallucinations, hypertension, tachycardia, mydriasis, and 
catalepsy. Laboratory analysis revealed hyperglycemia, 
glycosuria and an increased white cell count. A urine drug 
screening resulted positive for cocaine and phencyclidine: 
this test didn’t reveal the presence of 5-MeO-DiPT. Symptoms 
were resolved within two hours after administration of 
lorazepam [87].  
 Meatherall described a 21-year-old man who arrived to 
the Emergency Department about 1.5 h after consuming a 
capsule to get high, named “Foxy”, and sold to him on the 
street: he presented no nausea, pain, or visual deficit, he was 
alert and oriented, the only relevant clinical observation was 
his inability to move his limbs. He denied taking any other 
recreational drug or alcohol. He had a blood pressure of 
122/56 mm Hg, with 106 pulses and a respiration rate of 20. 
His pupils were equal and reactive with intact extra ocular 
movements and there was no motor sensory deficit. His 
cardiorespiratory examination was unremarkable. The 
patient received medical support until the symptoms did not 
disappear, about 3.5 hours after ingestion, then he was 
discharged from hospital. The toxicological analysis performed 
on the urine sample did not show presence of alcohol, but the 
immunoassay screening test was positive to cannabinoids 
and opiates: these results were, then, confirmed by GC/MS 
analysis. Acetaminophen and caffeine were detected in the 
acid-neutral drug screen performed with GC/MS. The 
GC/MS basic drug screen, indeed, revealed a large 5-MeO-
DiPT peak, codeine, nicotine, cotinine, acetaminophen, 
caffeine, and two other peaks that were assumed to be 5-
MeO-DiPT metabolites. The quantification of 5-MeO-DiPT 
was performed by GC/MS resulting at a concentration of 1.7 
µg/mL in the urine sample [88].  
 The review of the American Association of Poison 
Control Centers’ Total Exposure Surveillance System (AAPCC 
TESS) database found 41 exposures to “Foxy” between 
April, 2002 and June, 2003, resulting in moderate to severe 
toxicity in 68% of these cases. Clinical effects commonly 
involved agitation (59%), hallucinations (39%), tachycardia 
(37%), hypertension (17%), and confusion (15%). Tremors 
and seizures were rare [89]. 
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 Shimizu described a case of intoxication in a 27-year-old 
Japanese businessman after a single ingestion of the mixture 
of methylone and 5-MeO-MiPT: he had no previous 
psychiatric or medical illness and he had never used 
recreational drugs as methamphetamine, MDMA or organic 
solvents. The patient referred only sleep irregularities: he 
reported that, to solve his sleep disturbance, decided to take a 
drug without professional consultation. Although he did not 
know in depth the chemical and physical characteristics of 
methylone, he believed it could help feel him free from 
insomnia. Then, he bought on the Internet, the drug 1 g as 
pure methylone powder: but, toxicological analysis performed 
on the substance indicated that drug was composed of about 
60% methylone (120 mg) and 38% 5-MeO-MiPT (76 mg). 
He took approximately 200 mg of the drug powder by oral 
administration and thirty minutes later, he started to feel 
nausea and sick in the stomach. When he arrived in hospital, 
he presented psychomotor excitement and he was shouting 
without apparent reason. He showed dilated pupils and 
sweating, pyrexia (37.8 °C), tachycardia (150 bpm) and his 
blood pressure was 144/81 mm Hg. After a gastric lavage a 
rapid drug screening device was used to examine a gastric 
fluid sample and urine: the assay systems showed no immuno-
reactivity for the most common drugs of abuse (phencyclidine, 
benzodiazepines, cocaine metabolites, amphetamine and 
methamphetamine, cannabinoids, opiates, barbiturates, and 
tricyclic antidepressants). He still exhibited symptoms of 
substance-induced psychomotor excitement, more than 3.5 h 
from drug administration. He was observed and received 
medical assistance until the following day, then discharged 
without any known sequel: however, he did not remember 
anything of what happened during acute intoxication [90]. 
 Jovel described a case involving a 20-year-old college 
student brought to the E.D. after the ingestion of a dietary 
supplement capsule named “Lucy-N-Nate” that contained 
the novel synthetic tryptamine 5-MeO-DALT in unknown 
concentration. Although denying any other illicit assumption, 
his urine toxicological screening resulted positive for 
cannabinoids and amphetamines. At the admission he displayed 
diaphoresis, agitation, combativeness, flushes and warm 
sensation. Heart beat rate showed marked tachycardia (180–
200 bpm) and tachypnea was observed. Benzodiazepines and 
haloperidol were administered in order to try to manage the 
patient’s severe agitation with few results, therefore clinicians 
decided to proceed to deeper sedation and intubation. 
Rhabdomyolisis and acute renal failure were observed but 
resolved with supportive measures and the patient after three 
days was transferred to the inpatient psychiatric unit, and  
the following day he was discharged without symptoms or 
psychiatric sequelae [91]. 
FATALITIES INVOLVING TRYPTAMINE MISUSE  
 The use of tryptamines with recreational purposes may 
be associated with a higher risk of overdose, or due to a 
wrong dosage, as the information on these compounds 
available on the Internet are exclusively based on the first-
hand personal accounts presented in discussion fora, or to a 
repeated administrations, because often the onset of the 
desired effects can occur at a distance of several hours from 
the assumption. 
 In February 2003, the Miami-Dade County Medical 
Examiner Department reported the first known death in the 
country related to the assumption of α-methyltryptamine 
(AMT). The case in Miami, involved a 22 years old college 
student who found deceased, about 12 hours after he 
confided to his roommate he was "taking hallucinating 
drugs" and he was able to "discover the secret of the 
universe". The roommate reported that he was shaking and 
sweating profusely, waving a knife, and threatening to 
commit suicide. The roommate tied him to the bed for his 
own protection and left him to "sleep it off". Approximately 
12 h later, the roommate discovered the man lying in bed 
unresponsive. From the scene was recovered an empty 1-g 
vial of AMT. Immunoassay analysis of urine and gastric 
contents performed with enzyme immunoassay technique 
were positive for amphetamines and the basic drug blood 
screen performed with GC/MS detected a small peak, later 
identified as AMT. Volatile substances were screened using 
headspace gas chromatography (GC/HS). Postmortem 
toxicological analysis performed on iliac vein blood, gastric 
contents, liver and brain revealed the presence of AMT in the 
following concentrations (Table 9) [92, 48]. 
 
Table 9. Concentrations of AMT in the specimens collecting 
during autopsy from Moffat. 
Specimen AMT Concentration 
Iliac vein blood 2.0 mg/L 
Gastric contents  
(48 g collected during autopsy) 
9.6 mg total  
Liver 24.7 mg/kg 
Brain 7.8 mg/kg 
 
 Several deaths have been attributed to AET (α-
ethyltryptamine) assumption: this compound, strictly related 
to α-methyltryptamine, has psychedelic, stimulant, and 
entactogenic effects. It was originally developed as an 
antidepressant (Monase®) by Upjohn chemicals company in 
the 1960s but it was withdrawn from potential commercial 
use, because of an unacceptable incidence of idiosyncratic 
agranulocytosis [19, 93].  
 Morano reported a case of a 19 years old female who 
ingested a glass of beer containing two ‘hits’ of white 
powder that she described as MDMA. After ingestion she 
became confused, vomited and had a cardiac arrest. Autopsy 
revealed bilateral “pulmonary edema and generalized visceral 
congestion with some epicardial petechiae”. Toxicological 
findings showed the following AET tissue distribution: 
blood (heart) 5.6 mg/L, urine 80.4 mg/L, vitreous 2.4 mg/L, 
bile 22.0 mg/L, stomach contents 52.9 mg.; in liver, kidney 
and brain AET was found in a concentration of 18.3 mg/g, 
24.0 mg/g and 16.2 mg/g respectively. MDMA was no 
revealed in autoptical samples [94].  
 Another case of fatal intoxication with AET is reported 
by Daldrup. After ingestion of α-ethyltryptamine a young 
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man developed agitation, hyperpyrexia: he showed effects 
similar to those known from intoxication with amphetamines, 
MAO inhibitors, and thymoleptics. The exact amount of  
α-ethyltryptamine taken are not known, but it could have 
been in the range of 700 mg. The level in postmortem blood 
was 1.1 mg/l. Malignant hyperthermia is discussed as a 
possible cause of death [95].  
 In 2005, a 25 years old white male was found dead in a 
national park, where he was camping with his family, the 
morning after consuming a herbal hallucinogenic extract 
containing β-carbolines and hallucinogenic tryptamines [96]. 
An autopsy was performed the day after the body was 
discovered and no anatomic cause of death was found. 
“External examination identified only the presence of lividity 
that was fixed on the posterior surface of the body, except  
in areas exposed to pressure. Internal examinations, both 
gross and microscopic, were unremarkable except for some 
tissue congestion and edema”. Toxicological analysis were 
performed on specimens (central and peripheral blood, urine, 
gastric contents, bile, kidney, brain, and liver) collected at 
autopsy. The heart blood and urine samples were tested for 
volatile substances (methanol, ethanol, acetone and isopropanol 
by headspace gas chromatography) and therapeutic and 
abused drugs: no ethanol or other volatile substances were 
detected. Diphenhydramine was detected exclusively in the 
urine sample. “An unidentified peak was detected in both the 
blood and urine specimen on the alkaline drug screen: 
subsequent mass spectral analysis identified the substance  
as 5-MeO-DMT”. In the heart blood sample was identified  
N,N-dimethyltryptamine (0.02 mg/L), 5-methoxy N,N-
dimethyltryptamine (1.88 mg/L), tetrahydroharmine (0.38 
mg/L), harmaline (0.07 mg/L), and harmine (0.17 mg/L). 
Tetrahydroharmine (THH) “was present in higher amounts 
than both harmaline and harmine in all samples with the 
exception of the gastric contents, where the amount of 
harmine was 10-fold greater than that of THH”. The medical 
examiner ruled that the cause of death in this case was 
hallucinogenic amine intoxication. 
 Tanaka reported a fatal case of intoxication with “Foxy” 
(5-methoxy-N,N-diisopropyltryptamine). The decedent (male 
A) was a 29-year-old. The male A was a sexual partner of 
male B, who injected an aqueous solution of 5-MeO-DiPT 
into the anus of male A using a dropper, with the aim of 
enhancing sexual pleasure. Following the rectal administration, 
male A showed adverse effects including abdominal 
symptoms and intense agitation, so he was rushed in hospital, 
but he died on the following day. “Autopsy findings revealed 
periarteritis nodosa, involving the heart and liver, an area of 
myocardial ischaemia, leukocytosis, advanced pulmonary 
congestion and pulmonary alveolar haemorrhage and 
periprostatic bleeding. Blood and urine specimens were 
submitted for toxicological examination”: 5-MeO-DiPT and 
its two metabolites, 5-hydroxy-N,N-diisopropyltryptamine 
(5-OH-DIPT) and 5-methoxy-N-isopropyltryptamine (5-MeO-
NIPT), were identified by LC–MS. The level of 5-MeO-
DIPT, 5-OH-DIPT and 5-MeO-NIPT in blood was 0.412, 
0.327 and 0.020 µg/ml, while their concentrations in urine 
sample were 1.67, 27.0 and 0.32 µg/ml, respectively. These 
blood and urine levels were higher than published data for 
such poisoning. “In addition, no ethanol, therapeutic and 
abused drugs were detected in serum and urine specimens in 
this case. Based on the autopsy and toxicological findings, 
the cause of death was acute cardiac failure due to neuro- 
toxocity resulting from an overdose of 5-MeO-DiPT ” [62]. 
Unconfirmed reports on the Erowid website hypothesized 
that a 100 mg dose was used rectally, while a normal dose 
would be 10 mg [97].  
 In some cases the death of users of tryptamines for 
recreational purposes, was not caused by overdose or 
incorrect dosages, but by changes in the state of 
consciousness that led to the outbreak of irrational behaviors, 
extremely dangerous.  
 A 26 years old male was killed after walking onto the 
slow lane of a motorway and being hit by a lorry. He was 
seen to walk in front of a heavy goods vehicle while he was 
grinning. “At the inquest it was reported that he had snorted 
350 mg of 5-MeO-DALT” [98] “(when the normal dose is 
25 mg) in a public house with a friend who bought 1 g of it 
over the Internet”. During the autopsy, the coroner found a 
significant head injury with a base of skull fracture, cerebral 
and pulmonary contusions. The pathologist recorded the 
cause of death as “fractured base of skull” [10]. 
 An initial toxicological investigation found that the 
postmortem femoral blood contained an atracurium breakdown 
product (laudanosine) and propofol, which presence is 
consistent with medical intervention. The blood alcohol 
concentration was 22 mg/dL. “A compound was detected in 
blood with a distinctive tryptamine-like UV spectrum, but 
tryptamine itself is also regularly observed as a putrefactive 
compound. No other drugs were detected”. Following 
“further information about the deceased's consumption of 5-
MeO-DALT, supplementary toxicological analysis of the 
post mortem femoral blood samples were undertaken, using 
liquid chromatography with mass spectrometry detection 
(LC–MS), as it can be difficult to distinguish between 
tryptamine and other naturally occurring tryptamine-related 
compounds and those with methoxytryptamine derivatives 
(including 5-MeO-DALT) with similar UV spectra”. LC–MS 
analysis indicated that the compound was 5-MeO-DALT, but 
there are no information about its quantification.  
 It was reported another case of death [99] of a man who, 
after ingesting Hawaiian baby woodrose seeds [100], jumped 
from a building: ergine was found in his post mortem blood 
and urine [11]. 
ANALYTICAL METHODS FOR TRYPTAMINES 
 Tryptamines are not routinary detected with common 
immunoassay-based techniques, leading, for example, to 
misunderstanding in diagnosis or therapy in Emergency 
Departments, as toxicological screening tests could result 
completely negative.  
 Extensive laboratory analysis is required for the 
identification of these compounds, involving the use of 
techniques with high selectivity and sensitivity such as mass 
spectrometry (MS). But, even using powerful instrumentations, 
the new substances could be missed, either because, working 
in a full-scan mode, reference mass spectra are not yet 
included in libraries, or because the fragments generated 
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Table 10. Abbreviations: Q, quadrupole; QQQ, triple quadrupole; SIM, selected-ion monitoring; SRM, selected reaction 
monitoring; MRM, multiple reaction monitoring; PIS, precursor ions selected; IDA, information-independent acquisition; 
SPE, solid phase extraction; LLE, liquid - liquid extraction; PP, protein precipitation; LOD, limit of detection; LOQ, limit 
of quantification. 
Ref. Tryptamine Matrix 
Sample 
Extraction 
LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Derivatization MS System GC Column LC Column 
[96] DMT 
Urine and 
blood 
LLE  10000  Q (SIM) 
XTerra®  
MS-C18 column (100 x 3.0 
mm, d.p.= 3.5 µm) 
 
[92] AMT 
Blood and 
tissues 
SPE   PFPA Q (SIM) 
16.5 m×0.25mm i.d. x 0.30 
µm 
 
[108] 
AMT 
5-MeO-DiPT 
Urine and 
blood 
SPE 1  acetic anhydride Q (SIM) 
HP-1ms (30m×0.25mm i.d., 
0.25 µm film thickness) 
 
[62] 
5-MeO-DiPT 
metabolites 
Urine and 
blood 
LLE  10  Q (SIM)  
semi-micro L-
column ODS (1.5 
mm i.d. x 150 mm) 
[85] 
5-MeO-DiPT 
metabolites 
Urine and 
serum 
LLE    ION TRAP 
DB-5MS column (30 m x 
0.25 mm, 0.25 µm film) 
 
[88] 
5-MeO-DiPT 
metabolites 
Urine and 
blood 
LLE    
ION TRAP 
(full-scan) 
DB-1 (15 m x 0.25 mm, 0.25 
µm film thickness) 
 
[112] 
5-MeO-DiPT 
metabolites 
Urine LLE   MSTFA 
Q (full scan) 
QQQ (PIS) 
DB-5MS (30 m x 0.25 mm 
i.d. x 0.25 µm film thickness) 
semi-micro L-
column ODS (1.5 
mm i.d. x 150 mm) 
[90] 
5-MeO-MiPT 
Metilone 
Powder     Q 
HP-5 (30 m x 0.25 mm i.d. x 
0.32 mm diameter) 
 
[104] 
AMT 
DMT 
DPT 
5-MeO-DiPT(*) 
Urine and 
blood 
SPE 5(*)   Q (SIM) 
ZB-1 (30 m x 0.25 mm i.d., 
0.25 µm) 
Luna® phenyl-
hexyl column  
(100 x 2.1 mm i.d., 
d.p.= 3 µm) 
[105] 
AMT 
DiPT 
DPT 
DMT 
MiPT 
5-MeO-DMT 
Plasma/Serum SPE 1 - 2,5   QQQ (MRM)  
Synergi Polar RP 
column (150 mm × 
2 mm i.d., 4 µm) 
[113] 
AMT 
DMT 
DET 
DPT 
DBT 
DIBT 
5-MeO-AMT 
5-MeO-DMT 
5-MeO-DiPT 
Synthesized 
substances 
Diluition 
500 - 
15000 
300 - 1000 
  Q HP-5MS (30m × 0.25µm i.d.)  
[109] 
4-OH-DiPT 
4-acetoxy-DiPT 
Urine SPE 11 - 16 36 - 53  Q (SIM)  
Electron Hipersil 
Gold (150 mm×4.6 
mm;5 µm) 
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Table 10. contd…. 
Ref. Tryptamine Matrix 
Sample 
Extraction 
LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Derivatization MS System GC Column LC Column 
[110] 
Psilocin 
(4-HO-MET) 
Urine and 
plasma 
Diluition    QQQ (SRM)   
[111] 
4-OH-MET 
DiPT 
DPT 
DMT 
Urine Diluition 3 - 10 5 - 10  QQQ (SRM)  
1.7 µm 100 mm × 2.1 mm 
Ethylene Bridged Hybrid 
(BEH)  
C18 column 
[106] 
5-MeO-2-Me-trypt. 
2-Ph-trypt. 
DALT 
DMT 
NMT 
DPT 
MiPT 
NiPT 
4-OH-DMT 
(Psilocin) 
4-OH-trypt. 
4-AcO-DiPT 
5-Me-DALT 
5,6-MD-DALT 
7-Me-DALT 
7-Et-DALT 
5-OH-DMT 
5-EtO-DALT 
5-BnO-trypt. 
5-MeO-trypt. 
Urine and 
plasma 
PP (urine) 
LLE (plasma) 
10 - 100 
1 - 100 
  
LTQ 
(full scan, PIS, 
IDA) 
 
TF Hypersil GOLD C18 
column (100×2.1mm, 
1.9µm) guarded by a TF 
Hypersil GOLD C18 
Drop-in guard cartridge 
and a TF Javelin column 
filter 
[114] 
5-MeO-DALT 
5-MeO-MiPT 
Seized 
crystal and 
powder 
Diluition    
Q (full scan) 
Orbitrap 
J&W 5% phenyl-
methylsilicone 
capillary column  
(17 m× 0.2 mm i.d., 
0.33 µm film thickness) 
Acclaim RSLC 
120 C18 analytical 
column (2.1 × 100 mm, 
2.2 µm particle size) 
[107] 
AMT 
DMT 
5-MeO-AMT 
DET 
DPT 
DBT 
5-MeO-DMT 
DiPT 
5-MeO-DiPT 
Seized 
powder 
Diluition 
Solid deposit of 
analyte doped 
matrix crystals 
(TOF) 
   
Q (full scan) 
TOF 
HP-5MS  
(30m×0.25µm i.d.) 
bonded 
stationary phase film, 
0.25 µm in thickness 
 
 
 
during the analysis in selected ion monitoring (SIM) show 
nondescript and not monitored fragmentation patterns [76].  
 Moreover, instrumental screening methods were 
developed also for other NPS, but they do not always include 
tryptamines [101-103].  
 Several analytical approaches for tryptamines were 
published in scientific literature since 2003. Both screening 
methods [104-107] and confirmatory methods were 
developed for the detection of tryptamine derivatives which 
had clinical and forensic relevance [62, 85, 88, 90, 92, 96, 
105, 106, 108-111], using the hyphenated chromatography 
(GC and LC) mass spectrometry approach. 
 Whole blood, serum, plasma and urine were used for 
clinical studies [85, 88, 90, 104, 110, 111], while several 
biological matrices were investigated for forensic purposes 
[62, 92, 96].  
 Different extraction methods and sample preparation 
procedures were proposed: liquid liquid extraction (LLE) 
[62, 85, 88, 96, 112], solid-phase extraction (SPE) [92, 104, 
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105, 108, 109, 111], dilution in solvent [107, 110, 111, 113, 
114] and protein precipitation (PP) [106]. 
 The separation techniques used were gas chromatography 
(GC) and High Performance Liquid Chromatography (HPLC): 
in some recent papers, Ultra High Performance Liquid 
Cromatography (UHPLC) was used providing a more 
efficient analysis in a shorter time [106, 111]. The separation 
techniques were coupled with mass spectrometers, mainly 
for forensic purposes. 
 Several analyzers were used: (1) a single quadrupole in 
full-scan mode [90, 107, 112-114] and in SIM mode [62, 92, 
96, 104, 108, 109]; (2) a quadrupole ion trap in full-scan 
mode [88]; (3) a triple quadrupole in the following analyzer 
mode: MRM, SRM, PIS, IDA and in full-scan mode [105, 
110-112]; (4) a high resolution Orbitrap [114]. It was also 
used a TOF analyzer with MALDI ionization system, in 
order to compare the fragmentation pattern with that 
obtained with other analyzers [107].  
 Results of analysis of substances seized from law 
enforcement agencies were published too [90, 107, 113, 114], 
resulting in a useful source of information for specialists, 
including the personnel working in Emergency Departments. 
When NPS are found, if a reference standard is not available, 
NMR is needed for structural elucidation. Infrared (IR) 
spectroscopy is another powerful tool for bulk analysis. 
Hugel reported both the IR spectra and MS spectra of  
N,N-dimethyltryptamine, N,N- diethyltryptamine, N,N-
dipropyltryptamine, and 5-methoxy-N,N- diisopropyltrypt- 
amine [115].  
 Key information of selected analytical methods reported 
in scientific literature is summarized in Table 10. 
CONCLUSIONS 
 Many psychoactive substances belong to the chemical 
class of tryptamines. There are old compounds known for 
their hallucinogenic properties, such as psilocybin in ‘Magic 
mushrooms’ and dimethyltryptamine (DMT) in Ayahuasca 
brews, and there are several New psychoactive substances 
(NPS), emerging drugs whose chemical structures are similar 
to other psychoactive compounds but not identical, so  
that they represent a “legal” alternative to internationally 
controlled drugs. The comprehensive review of the published 
literature carried out permitted to find not only many 
scientific publications but also useful information from  
non peer-reviewed sources, including media reports  
and Internet resources such as drug user web fora. It was 
possible to collect and organize information on chemical 
characterization, pharmacology and toxicity of these drugs, 
according to a proposed classification based on their 
chemical structures. The articles, reporting cases of death 
related to intake of these substances, showed the need of 
more effective policies to promote timely exchange of 
information. Internet is “a growing source of on-line drug 
trafficking”: products purchased on Internet may vary over 
time proposing chemicals always different, not listed in 
literature, meaning that users are often unaware of what or 
how much they are taking, causing increasing risks to public 
health. For this reason information from Internet, together 
with results of analysis of substances seized from law 
enforcement agencies and reports of cases of death related to 
intake of these substances, organized in the way we proposed 
in this review, provides an effective tool for specialists 
facing this emerging threat to public health and public 
security, not only forensic scientists but also the personnel 
working in Emergency Departments.  
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